Skip to main content
SpringerLink
Log in

Morphine/Dextromethorphan — Endo

E 3231, Morphidex

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Caruso FS, Minn FL, Mao J, et al. NMDA antagonists enhance the analgesic properties of opiates. International Journal of Tissue Reactions 19: 28, No. 1/2, 1997

    Google Scholar 

  2. Algos Pharmaceutical Corporation. Algos Pharmaceutical Corporation releases results of phase III clinical trials for its lead product MorphiDex-tm. Media Release: [2 pages], 15 Sep 1998

    Google Scholar 

  3. Algos Pharmaceutical Corporation. Algos Pharmaceutical Corporation announces additional phase III clinical trial data for its lead product MorphiDex. Media Release: [2 pages], 25 Sep 1998

    Google Scholar 

  4. Endo Pharmaceuticals Holdings Inc. Endo Pharmaceuticals Announces Results from MorphiDex(R) Phase III Clinical Trial. Media Release: 24 Jun 2002. Available from URL: http://www.endo.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morphine/Dextromethorphan — Endo. Drugs in R&D 4, 55–56 (2003). https://doi.org/10.2165/00126839-200304010-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304010-00010

Keywords

Search

Navigation